Probucol suppresses osteoclastogenesis via activating Nrf2 signaling and ameliorates ovariectomy-induced bone loss

[Display omitted] •Probucol suppresses RANKL-induced osteoclast formation and function.•Probucol inhibits RANKL-induced oxidative stress, MAPKs and NF-κB signaling pathways.•Probucol inhibits osteoclastogenesis by regulating Nrf2.•Probucol can alleviate bone loss caused by estrogen deficiency. Osteo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2023-03, Vol.116, p.109820-109820, Article 109820
Hauptverfasser:	Guo, Jiachao, Ren, Ranyue, Guo, Zhou, Sun, Kai, He, Jinpeng, Shao, Jingfan, Wang, Xiaolin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antioxidants - pharmacology Antioxidants - therapeutic use Bone Resorption - drug therapy Bone Resorption - etiology Cell Differentiation Female Humans NF-E2-Related Factor 2 - genetics NF-E2-Related Factor 2 - metabolism NF-kappa B - metabolism Nrf2 Osteoclast Osteoclasts Osteogenesis Osteoporosis Osteoporosis - drug therapy Osteoporosis - etiology Ovariectomy - adverse effects Probucol Probucol - pharmacology Probucol - therapeutic use RANK Ligand - metabolism RANKL Reactive Oxygen Species - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!